Cargando…

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Morré, D. James, Hostetler, Brandon, Taggart, David J., Morré, Dorothy M., Musk, A. W., Robinson, Bruce W. S., Creaney, Jenette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724078/
https://www.ncbi.nlm.nih.gov/pubmed/26807072
http://dx.doi.org/10.1186/s12014-016-9103-3
_version_ 1782411526702891008
author Morré, D. James
Hostetler, Brandon
Taggart, David J.
Morré, Dorothy M.
Musk, A. W.
Robinson, Bruce W. S.
Creaney, Jenette
author_facet Morré, D. James
Hostetler, Brandon
Taggart, David J.
Morré, Dorothy M.
Musk, A. W.
Robinson, Bruce W. S.
Creaney, Jenette
author_sort Morré, D. James
collection PubMed
description BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a recently identified marker of malignancy, were investigated using the ONCOblot tissue of origin cancer detection test. METHODS: Sequential serum samples collected from asbestos-exposed individuals prior to the development of frank mesothelioma were assayed for ENOX2 presence by 2-D gel immunoblot analysis to determine how long in advance of clinical symptoms mesothelioma-specific ENOX2 transcript variants could be detected. RESULTS: Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4–10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years). Either one or both ENOX2 protein transcript variants indicative of malignant mesothelioma were absent in 14 of 15 subjects diagnosed with benign pleural plaques either with or without accompanying asbestosis. CONCLUSIONS: In a population of asbestos-exposed subjects who eventually developed malignant mesothelioma, ENOX2 protein transcript variants characteristic of malignant mesothelioma were present in serum 4–10 years in advance of clinical symptoms. As with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling.
format Online
Article
Text
id pubmed-4724078
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47240782016-01-24 ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms Morré, D. James Hostetler, Brandon Taggart, David J. Morré, Dorothy M. Musk, A. W. Robinson, Bruce W. S. Creaney, Jenette Clin Proteomics Research BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a recently identified marker of malignancy, were investigated using the ONCOblot tissue of origin cancer detection test. METHODS: Sequential serum samples collected from asbestos-exposed individuals prior to the development of frank mesothelioma were assayed for ENOX2 presence by 2-D gel immunoblot analysis to determine how long in advance of clinical symptoms mesothelioma-specific ENOX2 transcript variants could be detected. RESULTS: Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4–10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years). Either one or both ENOX2 protein transcript variants indicative of malignant mesothelioma were absent in 14 of 15 subjects diagnosed with benign pleural plaques either with or without accompanying asbestosis. CONCLUSIONS: In a population of asbestos-exposed subjects who eventually developed malignant mesothelioma, ENOX2 protein transcript variants characteristic of malignant mesothelioma were present in serum 4–10 years in advance of clinical symptoms. As with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling. BioMed Central 2016-01-22 /pmc/articles/PMC4724078/ /pubmed/26807072 http://dx.doi.org/10.1186/s12014-016-9103-3 Text en © Morré et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Morré, D. James
Hostetler, Brandon
Taggart, David J.
Morré, Dorothy M.
Musk, A. W.
Robinson, Bruce W. S.
Creaney, Jenette
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
title ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
title_full ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
title_fullStr ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
title_full_unstemmed ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
title_short ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
title_sort enox2-based early detection (oncoblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724078/
https://www.ncbi.nlm.nih.gov/pubmed/26807072
http://dx.doi.org/10.1186/s12014-016-9103-3
work_keys_str_mv AT morredjames enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms
AT hostetlerbrandon enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms
AT taggartdavidj enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms
AT morredorothym enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms
AT muskaw enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms
AT robinsonbrucews enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms
AT creaneyjenette enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms